Mechanism of Action and Chemical Structure
How Polyenes Attack Fungal Cells
Polyene antifungals work by exploiting key differences between fungal and human cell membranes. These drugs contain a polyene macrolide structure with multiple conjugated double bonds. This structure allows them to bind specifically to ergosterol, the primary sterol in fungal cell membranes.
Human cell membranes contain cholesterol instead of ergosterol. This difference provides selective toxicity for fungal cells over human cells.
The Pore Formation Process
Once amphotericin B or nystatin binds to ergosterol, it forms aqueous pores in the fungal cell membrane. These pores allow cellular contents to leak out, including potassium, magnesium, and other essential nutrients. This leads to cell lysis and death.
The polyene structure is crucial to this binding. The rigid, extended conjugated system allows the drug to insert into the membrane at the correct orientation.
Structural Differences and Clinical Implications
Amphotericin B is a heptaene (seven double bonds). Nystatin is a tetraene (four double bonds). These differences explain variations in their potency and spectrum. This mechanism is fungistatic at low concentrations and fungicidal at higher concentrations.
Resistance is rare because ergosterol is essential for fungal survival. Organisms cannot modify ergosterol without destroying their own membrane function.
Amphotericin B: Classification, Formulations, and Clinical Use
Formulations and Their Toxicity Profiles
Amphotericin B is one of the most important antifungal agents for serious systemic infections. The drug exists in several formulations, each with distinct properties.
Conventional amphotericin B uses deoxycholate. It remains highly effective but causes significant nephrotoxicity and infusion-related reactions.
Lipid formulations were developed to reduce toxicity. They include:
- Liposomal amphotericin B (LAmB) uses liposomes
- Amphotericin B lipid complex (ABLC) uses lipid complexes
- Amphotericin B colloidal dispersion (ABCD) uses colloid technology
These formulations preferentially deliver the drug to infected tissues. They reduce exposure to kidneys and other organs.
Clinical Applications
Amphotericin B has broad-spectrum activity against:
- Yeasts: Candida species, Cryptococcus neoformans
- Molds: Aspergillus species, Mucor
It is the gold standard for treating invasive candidiasis, cryptococcal meningitis, and invasive aspergillosis.
The drug is given intravenously. It has poor oral bioavailability, so oral routes are not viable.
Monitoring and Management
Important monitoring includes renal function tests and electrolyte panels, especially potassium and magnesium. Watch for infusion-related reactions such as fever, chills, and rigors.
Pre-medication with acetaminophen, NSAIDs, or corticosteroids can reduce reaction severity.
Nystatin: Topical and Oral Applications
Clinical Role and Absorption
Nystatin is a polyene antifungal with a narrower clinical role than amphotericin B. It remains essential for superficial and mucosal fungal infections.
Unlike amphotericin B, nystatin is poorly absorbed from the gastrointestinal tract. It is primarily used for local effects on mucosal surfaces.
Available Formulations
Nystatin is available in multiple formulations:
- Oral suspension
- Tablets
- Topical cream
- Ointment
- Powder
Treatment of Oral Candidiasis
Nystatin oral suspension is the preferred treatment for oral candidiasis (thrush). It works particularly well in immunocompromised patients, infants, and those taking broad-spectrum antibiotics.
The medication coats the mucosa and eliminates Candida albicans locally. Dosing typically requires frequent administration (4 to 6 times daily) to maintain local drug concentrations.
Other Clinical Uses
For vaginal candidiasis, nystatin vaginal tablets are available. Azoles are often preferred due to shorter treatment duration.
Topical nystatin cream or powder treats cutaneous and intertriginous candidiasis, athlete's foot, and other fungal skin infections.
One advantage of nystatin is its relatively low systemic toxicity. This is due to minimal absorption when used topically or orally.
Compliance can be challenging due to frequent dosing requirements and the unpleasant taste of oral suspension. Nystatin is also used prophylactically in severely immunocompromised patients. However, fluconazole is increasingly preferred for this indication.
Adverse Effects and Toxicity Profiles
Amphotericin B Toxicity Overview
Amphotericin B has a notorious toxicity profile. It is described as extremely toxic but necessary for life-threatening fungal infections.
Nephrotoxicity: The Primary Concern
The most significant adverse effect is nephrotoxicity. This occurs in up to 80% of patients receiving conventional amphotericin B. This manifests as elevated serum creatinine, reduced glomerular filtration rate, and electrolyte wasting.
Potassium and magnesium wasting particularly occurs. Lipid formulations significantly reduce nephrotoxicity but are considerably more expensive.
Infusion-Related Reactions
Infusion-related reactions include fever, chills, rigors, headache, and malaise. These occur during or shortly after infusion. These reactions decrease with continued therapy but can be severe.
Additional Adverse Effects
Electrolyte abnormalities including hypokalemia and hypomagnesemia require careful monitoring and supplementation. Anemia and thrombocytopenia can occur with prolonged therapy.
Amphotericin B also causes phlebitis at infusion sites. It should be administered through central lines when possible.
Nephrotoxicity Prevention Strategies
Nephrotoxicity can be reduced by:
- Maintaining adequate hydration
- Using slower infusion rates
- Avoiding concurrent nephrotoxic drugs
- Administering sodium loading
- Using lipid formulations preferentially
Nystatin Adverse Effects
Nystatin has significantly fewer systemic adverse effects due to its topical/local use and poor absorption. Local side effects include nausea, vomiting, diarrhea, and abdominal pain with oral formulations.
Rare hypersensitivity reactions and contact dermatitis with topical use have been reported. Teratogenicity concerns are minimal with both drugs, making them relatively safe in pregnancy.
Resistance, Drug Interactions, and Clinical Pearls
Why Resistance Is Extremely Rare
Resistance to polyene antifungals is remarkably uncommon. Ergosterol is fundamental to fungal cell membrane integrity. True resistance requires major alterations to membrane composition. These alterations typically render organisms non-viable.
However, reduced susceptibility has been documented in rare Candida and Aspergillus strains. This is often associated with decreased ergosterol content or altered membrane composition. Some Cryptococcus gattii strains demonstrate higher minimum inhibitory concentrations (MICs) to amphotericin B.
Heteroresistance occurs when subpopulations within a strain show variable susceptibility. This can complicate clinical outcomes.
Drug Interactions with Amphotericin B
Drug interactions with amphotericin B include potentiation of nephrotoxicity with:
- Aminoglycosides
- NSAIDs
- ACE inhibitors
Corticosteroids combined with amphotericin B increase hypokalemia risk. Flucytosine combined with amphotericin B creates synergistic activity against Candida and Cryptococcus.
Essential Clinical Pearls
Key practice points include:
- Amphotericin B should be reconstituted in dextrose-containing solutions, not saline
- The drug cannot be filtered with standard bacterial filters
- Test doses are rarely used anymore
- Baseline renal function and electrolytes must be established
- Lipid formulations should be considered for patients with renal impairment
- Use lipid formulations for those receiving concurrent nephrotoxic agents
Nystatin Interactions
Nystatin resistance is essentially non-existent in clinical practice. Drug interactions are minimal. Understanding these factors is critical for safe and effective polyene antifungal therapy. This knowledge is essential for healthcare professionals and students.